Sobi will pay $75 million upfront to Innate Pharma for rights to market lacutamab, agreeing to a total deal value of $580 million ahead of a planned Phase 3 push. The transaction gives Sobi market access for the anti-KIR3DL2 antibody in an aggressive skin cancer setting where Innate previously generated early signals. The deal is structured as an option-style entry into commercialization rights, with the larger economics tied to future milestones. For Sobi, bringing lacutamab into its portfolio expands exposure to oncology immunotherapy mechanisms aimed at modulating inhibitory receptor biology. The announcement highlights how sponsors are using partnership economics to manage development risk—buying into clinical momentum while reserving the biggest payments for later-stage confirmation.